Song Jianlu, Xu Ruiyuan, Zhang Hui, Xue Xuemin, Ruze Rexiati, Chen Yuan, Yin Xinpeng, Wang Chengcheng, Zhao Yupei
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; National Science and Technology Key Infrastructure on Translational Medicine in Peking Union Medical College Hospital, Beijing, People's Republic of China; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China.
Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Gastroenterology. 2023 Dec;165(6):1505-1521.e20. doi: 10.1053/j.gastro.2023.08.035. Epub 2023 Aug 30.
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with high intratumoral heterogeneity. There is a lack of effective therapeutics for PDAC. Entosis, a form of nonapoptotic regulated cell death mediated by cell-in-cell structures (CICs), has been reported in multiple cancers. However, the role of entosis in PDAC progression remains unclear.
CICs were evaluated using immunohistochemistry and immunofluorescence staining. The formation of CICs was induced by suspension culture. Through fluorescence-activated cell sorting and single-cell RNA sequencing, entosis-forming cells were collected and their differential gene expression was analyzed. Cell functional assays and mouse models were used to investigate malignant phenotypes. Clinical correlations between entosis and PDAC were established by retrospective analysis.
Entosis was associated with an unfavorable prognosis for patients with PDAC and was more prevalent in liver metastases than in primary tumors. The single-cell RNA sequencing results revealed that several oncogenes were up-regulated in entosis-forming cells compared with parental cells. These highly entotic cells demonstrated higher oncogenic characteristics in vitro and in vivo. NET1, neuroepithelial cell transforming gene 1, is an entosis-related gene that plays a pivotal role in PDAC progression and is correlated with poor outcomes.
Entosis is correlated with PDAC progression, especially in liver metastasis. NET1 is a newly validated entosis-related gene and a molecular marker of poor outcomes. PDAC cells generate a highly aggressive subpopulation marked by up-regulated NET1 via entosis, which may drive PDAC progression.
胰腺导管腺癌(PDAC)是一种具有高度肿瘤内异质性的致命恶性肿瘤。目前缺乏针对PDAC的有效治疗方法。细胞内陷是一种由细胞内细胞结构(CICs)介导的非凋亡性调节性细胞死亡形式,已在多种癌症中报道。然而,细胞内陷在PDAC进展中的作用仍不清楚。
采用免疫组织化学和免疫荧光染色评估CICs。通过悬浮培养诱导CICs的形成。通过荧光激活细胞分选和单细胞RNA测序,收集形成细胞内陷的细胞并分析其差异基因表达。使用细胞功能测定和小鼠模型研究恶性表型。通过回顾性分析建立细胞内陷与PDAC之间的临床相关性。
细胞内陷与PDAC患者的不良预后相关,在肝转移中比在原发性肿瘤中更普遍。单细胞RNA测序结果显示,与亲代细胞相比,形成细胞内陷的细胞中几种癌基因上调。这些高度细胞内陷的细胞在体外和体内均表现出更高的致癌特征。NET1(神经上皮细胞转化基因1)是一种与细胞内陷相关的基因,在PDAC进展中起关键作用,并与不良预后相关。
细胞内陷与PDAC进展相关,尤其是在肝转移中。NET1是一个新验证的与细胞内陷相关的基因,也是不良预后的分子标志物。PDAC细胞通过细胞内陷产生以NET1上调为特征的高度侵袭性亚群,这可能推动PDAC进展。